Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
TPST 11.25.2024
About Gravity Analytica
Recent News
- 01.06.2025 - Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
- 12.06.2024 - Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 12.03.2024 - Piper Sandler 36th Annual Healthcare Conference
Recent Filings
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classitargeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00 a.m. ET.
To access the live or archived recording of the discussion, please visit the investor section of the Tempest website athttps://ir.tempesttx.com.
About Tempest TherapeuticsTempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website atwww.tempesttx.com.
Investor Contacts:
Sylvia WheelerWheelhouse Life Science Advisorsswheeler@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science Advisorsareynolds@wheelhouselsa.com
_______________________________iIf approved by the FDA
